FI970244A0 - Förfarande för att stabilisera sekretionen av tonisk ovarieestrogen för fortsatta vård - Google Patents

Förfarande för att stabilisera sekretionen av tonisk ovarieestrogen för fortsatta vård

Info

Publication number
FI970244A0
FI970244A0 FI970244A FI970244A FI970244A0 FI 970244 A0 FI970244 A0 FI 970244A0 FI 970244 A FI970244 A FI 970244A FI 970244 A FI970244 A FI 970244A FI 970244 A0 FI970244 A0 FI 970244A0
Authority
FI
Finland
Prior art keywords
therapies
secretion
continued
ovarian estrogen
method stabilizes
Prior art date
Application number
FI970244A
Other languages
English (en)
Finnish (fi)
Other versions
FI970244A (sv
Inventor
Gary D Hodgen
Audrey Philips
Original Assignee
Hampton Roads Medical College
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI970244(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Hampton Roads Medical College, Ortho Pharma Corp filed Critical Hampton Roads Medical College
Publication of FI970244A0 publication Critical patent/FI970244A0/sv
Publication of FI970244A publication Critical patent/FI970244A/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI970244A 1994-07-22 1997-01-21 Förfarande för att stabilisera sekretionen av tonisk ovarieestrogen för fortsatta vård FI970244A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number Publication Date
FI970244A0 true FI970244A0 (sv) 1997-01-21
FI970244A FI970244A (sv) 1997-01-21

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970244A FI970244A (sv) 1994-07-22 1997-01-21 Förfarande för att stabilisera sekretionen av tonisk ovarieestrogen för fortsatta vård

Country Status (29)

Country Link
EP (1) EP0769956B1 (sv)
JP (1) JP3138477B2 (sv)
CN (1) CN1137722C (sv)
AP (1) AP775A (sv)
AT (1) ATE190494T1 (sv)
AU (1) AU691952B2 (sv)
BG (1) BG63363B1 (sv)
BR (1) BR9508718A (sv)
CA (1) CA2195745C (sv)
CY (1) CY2228B1 (sv)
CZ (1) CZ291803B6 (sv)
DE (1) DE69515666T2 (sv)
DK (1) DK0769956T3 (sv)
EE (1) EE03515B1 (sv)
ES (1) ES2145286T3 (sv)
FI (1) FI970244A (sv)
GR (1) GR3033590T3 (sv)
HU (1) HU218910B (sv)
IL (1) IL114655A (sv)
IS (1) IS4413A (sv)
LV (1) LV11823B (sv)
MX (1) MX9700574A (sv)
NO (1) NO970257L (sv)
NZ (1) NZ290554A (sv)
OA (1) OA10730A (sv)
PT (1) PT769956E (sv)
RU (1) RU2181598C2 (sv)
SK (1) SK282118B6 (sv)
WO (1) WO1996003138A1 (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
NZ534836A (en) * 1999-09-23 2007-07-27 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US20110129532A1 (en) * 2008-05-29 2011-06-02 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
WO2016184829A1 (en) * 2015-05-18 2016-11-24 Nerre Therapeutics Limited Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
JP3138477B2 (ja) 2001-02-26
AP9700913A0 (en) 1997-01-31
ATE190494T1 (de) 2000-04-15
IL114655A (en) 2005-08-31
DK0769956T3 (da) 2000-06-05
JPH10503203A (ja) 1998-03-24
OA10730A (en) 2001-06-07
AP775A (en) 1999-10-28
EE9700208A (et) 1998-02-16
CY2228B1 (en) 2003-04-18
ES2145286T3 (es) 2000-07-01
HU218910B (hu) 2000-12-28
EP0769956B1 (en) 2000-03-15
NZ290554A (en) 2000-08-25
RU2181598C2 (ru) 2002-04-27
WO1996003138A1 (en) 1996-02-08
NO970257D0 (no) 1997-01-21
IL114655A0 (en) 1995-11-27
LV11823A (lv) 1997-08-20
EE03515B1 (et) 2001-10-15
PT769956E (pt) 2000-07-31
CN1200674A (zh) 1998-12-02
CZ291803B6 (cs) 2003-06-18
DE69515666T2 (de) 2000-07-06
IS4413A (is) 1997-01-14
HUT77127A (hu) 1998-03-02
CZ15097A3 (en) 1997-11-12
HU9700046D0 (en) 1997-02-28
SK7097A3 (en) 1997-11-05
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
AU3132095A (en) 1996-02-22
BG101158A (en) 1997-09-30
BG63363B1 (bg) 2001-11-30
NO970257L (no) 1997-01-21
EP0769956A1 (en) 1997-05-02
DE69515666D1 (de) 2000-04-20
LV11823B (en) 1998-03-20
MX9700574A (es) 1997-12-31
AU691952B2 (en) 1998-05-28
CN1137722C (zh) 2004-02-11
FI970244A (sv) 1997-01-21
CA2195745A1 (en) 1996-02-08
BR9508718A (pt) 1997-12-30
CA2195745C (en) 2005-03-29
SK282118B6 (sk) 2001-11-06

Similar Documents

Publication Publication Date Title
DK0785792T3 (da) Præparat til behandling af ovariale af østrogen afhængige sygdomme
FI940374A0 (sv) Metod för excitering av färgämnen
NO953282D0 (no) Fremgangsmåte for bedring av produktiviteten til en brönn
DE69533913D1 (de) Frequenzsynthesizer
DE69635573D1 (de) Frequenzsynthetisierer
FI921026A0 (sv) Förfarande för stabilisering av referensfrekvensen i en radiotelefon
DE69616022T2 (de) Frequenzsynthetisierer
NO971807D0 (no) To-trinns fremgangsmåte for separasjon
FI945343A0 (sv) Förfarande och koppling för alstring frekvenser i Förfarande och koppling för alstring frekvenser i en radiotelefon en radiotelefon
DE69600347T2 (de) Frequenzsynthetisierer
NO983913D0 (no) Fremgangsmåte for oppfanging av tioler
FI970244A0 (sv) Förfarande för att stabilisera sekretionen av tonisk ovarieestrogen för fortsatta vård
FI963018A (sv) Förfarande för framställning av gammapyroner
ZA956099B (en) Method of establishing tonic ovarian estrogen secretion for extended therapeutic regimens.
FI952104A0 (sv) Förfarande för framställning av pulver av oorganiska föreningar
FI972694A (sv) Nytt förfarande för framställning av sameridin
DE69523018D1 (de) Frequenzteiler
FI953291A (sv) Förfarande för separation av meta- och paraetylfenol
FR2734957B1 (fr) Armement-traverse a fixation rapide pour travaux sous-tension
FI102975B1 (sv) Förfarande för styrning av en process för framställning av slipmassa
FI954359A0 (sv) Sätt och anordning för reducering av dagöppningen hos en brunn
KR950034488U (ko) 발진주파수 제어방법
KR960020187U (ko) 저주파 전침기
LV10943A (lv) N-benziloksikarbonilarginina 4-metilkumaril-7-amida iegusanas metode
UA26019C2 (uk) Спосіб підготовки кристалу до обточуваhhя

Legal Events

Date Code Title Description
FC Application refused